Guidance

Principles for control of non-HCID mpox in the UK: 4 nations consensus statement

A consensus statement outlining principles for the control of non-high-consequence infectious disease (HCID) mpox (monkeypox) in healthcare and other settings in the UK.

From:
UK Health Security Agency, Public Health Wales and Public Health Agency (Northern Ireland)
Published
30 May 2022
Last updated
31 October 2024 — See all updates

Documents

Principles for control of non-HCID mpox in the UK: 4 nations consensus statement

HTML

Details

This document outlines strategic aims for controlling non-HCID mpox, assumptions about mpox transmission and biology, and implications for domestic/community, ambulatory care, inpatient healthcare and other residential settings.

This statement has been agreed by the UK public health agencies: UK Health Security Agency, Public Health Scotland, Public Health Wales and Public Health Agency Northern Ireland.

Updates to this page

Published 30 May 2022
Last updated 31 October 2024 + show all updates

  1. Minor update to reflect the first detection of clade I mpox in the UK.

  2. Updated links to direct to the Green Book chapter 29.

  3. Updated in line with HCID derogation of Clade II MPXV (monkeypox virus). Added new section on cleaning and decontamination.

  4. Updated strategic aims.

  5. Updated text about evidence of pre-symptomatic transmission.

  6. Updated to reflect the change in monkeypox clade nomenclature.

  7. Amended in line with introduction of highly probable case definition.

  8. Updated to reflect changes in management of contacts of a confirmed case of monkeypox.

  9. Updated guidance, including information on using a condom after recovering from infection.

  10. Updated to reflect HCID derogation of the current outbreak of monkeypox, and changes to active monitoring of contacts.

  11. First published.

Sign up for emails or print this page

Related content